Musculoskeletal Pain Market Set to Observe Remunerative Growth During the Study Period (2019-2032) | DelveInsight
The emergence of new products in the pipeline will add to the musculoskeletal pain market growth in the future. In addition, persistently rising cases of chronic pain in the forecast period will help increase the musculoskeletal pain treatment market.
New York, USA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- *Musculoskeletal Pain Market Set to Observe Remunerative Growth During the Study Period (2019-2032) | DelveInsight *
*The emergence of new products in the pipeline will add to the musculoskeletal pain market growth in the future. In addition, persistently rising cases of chronic pain in the forecast period will help increase the musculoskeletal pain treatment market.*
DelveInsight’s *Musculoskeletal Pain Market Insights* report includes a comprehensive understanding of current treatment practices, musculoskeletal pain emerging drugs, market share of individual therapies, and current and forecasted musculoskeletal pain market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
*Key Takeaways from the Musculoskeletal Pain Market Report*
· As per DelveInsight’s analysis, the musculoskeletal pain market size was found to be *USD 3.6 billion* in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, the total 7MM diagnosed prevalent cases of musculoskeletal pain in 2021 were over *146 million*, out of which the highest cases were observed in the United States.
· Leading musculoskeletal pain companies such as *Virios Therapeutics, Mesoblast, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Eli Lilly and Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Techfields Pharma, Camurus, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Teva Pharmaceutical Industries, Propella Therapeutics, Novartis Pharmaceuticals, Sun Pharmaceutical Industries, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, Charleston Laboratories, *and others are developing novel musculoskeletal pain drugs that can be available in the musculoskeletal pain market in the coming years.
· Some of the key therapies for musculoskeletal pain treatment include *Rexlemestrocel-L (MPC-06-ID), Fasinumab, Resiniferatoxin, TLC599, LY3556050, LY3016859, Esreboxetine (AXS-14), Lorecivivint, CNTX-4975, Ampion, X0002, IMC-1, Buprenorphine/CAM2038, TG-C/INVOSSA/Tonogenchoncel-L, AMZ001, Joyclu, Fremanezumab, CGS-200-5, DFV890, Canakinumab, MM-II, Otenaproxesul/ATB-346, NOVOCART 3D, StroMed + platelet-rich plasma (PRP), XT-150, TNX-102 SL, ACP-044, MEDI7352, CL-108**, *and others.
Discover which therapies are expected to grab the major musculoskeletal pain market share @ *Musculoskeletal Pain Market Report*
*Musculoskeletal Pain Overview*
Musculoskeletal pain refers to persistent or recurrent pain affecting the bones, muscles, ligaments, tendons, and nerves. Pain associated with musculoskeletal (MSK) disorders is a prevalent issue with significant medical and socioeconomic implications worldwide. Chronic musculoskeletal pain, notably low back pain, stands as a leading cause of global disability. According to the World Health Organization (WHO), 20–33% of the world's population grapples with some form of chronic musculoskeletal pain, equating to approximately 1.75 billion individuals worldwide. The Pain Task Force of the International Association for the Study of Pain (IASP) defines chronic primary musculoskeletal pain (CPMP) as persistent pain in the muscles, bones, joints, or tendons, accompanied by substantial emotional distress (such as anxiety, anger, frustration, and depression) or functional impairment.
*Musculoskeletal Pain Epidemiology Segmentation*
The musculoskeletal pain epidemiology section provides insights into the historical and current musculoskeletal pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The *musculoskeletal pain market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Musculoskeletal Pain Diagnosed Prevalent Cases
· Musculoskeletal Pain Gender-specific Cases
· Musculoskeletal Pain Age-specific Cases
Download the report to understand which factors are driving musculoskeletal pain epidemiology trends @ *Musculoskeletal Pain Epidemiological Insights*
*Musculoskeletal Pain Treatment Market *
Traditionally, NSAIDs were the standard approach to treating musculoskeletal pain. Existing research suggests a moderate level of evidence supporting their efficacy. Nonetheless, there is also moderate evidence indicating the effectiveness of pharmacological therapies for short-term musculoskeletal pain relief. Therefore, options like NSAIDs, Cox-2 selective inhibitors, and opioids have demonstrated the capacity to alleviate pain in the short term. However, it's essential to recognize that the impact of these treatments is relatively modest, and potential adverse effects such as gastrointestinal bleeding and opioid-induced hyperalgesia must be approached with caution. In the market, there are several drugs available for musculoskeletal pain relief, including *Zilretta, Cingal, Cymbalta, Drizalma Sprinkle, and Loqoa Tape*.
*Zilretta *made history in October 2017 as the first and only extended-release, intra-articular therapy sanctioned by the US FDA for patients dealing with knee pain due to osteoarthritis by functioning as glucocorticoid receptor agonists. The company embarked on a full-scale commercial launch in November 2017. Although current evidence points to its effectiveness in providing short-term relief for shoulder and knee pain, its impact on back and neck pain remains uncertain.
Within the realm of osteoarthritis treatment, *Cingal *has emerged as a game-changer, securing approval in the European Union due to its remarkable effectiveness in managing associated pain. This groundbreaking medication is composed of FDA-approved triamcinolone hexacetonide, a powerful anti-inflammatory steroid, and cross-linked sodium hyaluronate. It is administered through intra-articular injection, acting as a potent glucocorticoid receptor agonist. Cingal’s simplicity shines through with its single-dose preparation, with the recommended dose set at 4 mL (equivalent to one syringe) per knee joint.
Learn more about the FDA-approved drugs for musculoskeletal pain @ *Drugs for* *Musculoskeletal Pain** Treatment*
*Key Musculoskeletal Pain Therapies and Companies*
· Rexlemestrocel-L (MPC-06-ID): Mesoblast
· Fasinumab: Regeneron Pharmaceuticals|Teva Pharmaceutical Industries|Mitsubishi Tanabe Pharma
· Resiniferatoxin: Sorrento Therapeutics
· TLC599: Taiwan Liposome Company
· LY3556050: Eli Lilly and Company
· LY3016859: Eli Lilly and Company
· Esreboxetine (AXS-14): Axsome Therapeutics
· Lorecivivint: Biosplice Therapeutics
· CNTX-4975: Centrexion Therapeutics
· Ampion: Ampio Pharmaceuticals
· X0002: Techfields Pharma
· IMC-1: Virios Therapeutics
· Buprenorphine/CAM2038: Camurus/Braeburn Pharmaceuticals
· TG-C/INVOSSA/Tonogenchoncel-L: Kolon TissueGene
· AMZ001: Amzell
· Joyclu: Seikagaku Corporation
· Fremanezumab: Teva Pharmaceutical Industries
· CGS-200-5: Propella Therapeutics
· DFV890: Novartis Pharmaceuticals
· Canakinumab: Novartis Pharmaceuticals
· MM-II: Sun Pharmaceutical Industries|Moebius Medical
· Otenaproxesul/ATB-346: Antibe Therapeutics
· NOVOCART 3D: Aesculap Biologics
· StroMed + platelet-rich plasma (PRP): VivaTech
· XT-150: Xalud Therapeutics
· TNX-102 SL: Tonix Pharmaceuticals
· ACP-044: ACADIA Pharmaceuticals
· MEDI7352: AstraZeneca
· CL-108: Charleston Laboratories
To know more about musculoskeletal pain clinical trials, visit @ *Musculoskeletal Pain Treatment Drugs*
*Musculoskeletal Pain Market Dynamics*
The dynamics of the musculoskeletal pain market are expected to change in the coming years. Numerous pharmaceutical companies are continually engaged in *research and innovation* to develop more effective treatment approaches for addressing the unmet needs of musculoskeletal pain. The *growing prevalence of musculoskeletal pain* conditions, such as knee pain related to osteoarthritis, is largely driven by the aging population, and this demographic shift is expected to significantly impact the musculoskeletal pain market in the near future. This study aims to identify potential therapeutic targets and strategies aimed at *enhancing the quality of life *and restoring functional capabilities in individuals suffering from chronic musculoskeletal pain.
Additionally, we seek to gain insights into the transition from acute to chronic musculoskeletal pain, explore the *manifestations of peripheral and central sensitization*, and examine methods for their assessment. Furthermore, we emphasize the importance of *robust patient education* on musculoskeletal disorders and pain syndromes to enhance the overall quality of care.
Furthermore, potential therapies are being investigated for the treatment of musculoskeletal pain, and it is safe to predict that the treatment space will significantly impact the musculoskeletal pain market during the forecast period. Moreover, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the musculoskeletal pain market in the 7MM.
However, several factors are impeding the growth of the musculoskeletal pain market. While extensive research has been conducted over the past several decades, the *root causes and underlying pathophysiology* of chronic musculoskeletal pain conditions remain elusive. Presently, the available non-opioid therapies, designed to mitigate the *risks of opioid dependence and abuse*, provide only limited relief and are frequently associated with notable adverse effects, such as gastrointestinal complications, organ dysfunction, and even mortality.
Chronic musculoskeletal pain, particularly low back pain, stands as a leading cause of global disability. The burden of musculoskeletal pain extends beyond the affected individuals, significantly impacting *patients, healthcare systems, and caregivers alike*. This burden manifests in various forms, including functional impairment, emotional distress, mood disturbances, loss of independence, and diminished overall quality of life. Managing musculoskeletal pain can be especially challenging, particularly in *patients with concurrent medical conditions*.
Furthermore, the musculoskeletal pain market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the musculoskeletal pain market growth.
*Musculoskeletal Pain Report Metrics* *Details*
Study Period 2019–2032
Musculoskeletal Pain Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Musculoskeletal Pain Market Size in 2021 USD 3.6 Billion
Key Musculoskeletal Pain Companies Virios Therapeutics, Mesoblast, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Sorrento Therapeutics, Taiwan Liposome Company, Eli Lilly and Company, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Ampio Pharmaceuticals, Techfields Pharma, Camurus, Braeburn Pharmaceuticals, Kolon TissueGene, Amzell, Seikagaku Corporation, Teva Pharmaceutical Industries, Propella Therapeutics, Novartis Pharmaceuticals, Sun Pharmaceutical Industries, Moebius Medical, Antibe Therapeutics, Aesculap Biologics, VivaTech, Xalud Therapeutics, Tonix Pharmaceuticals, ACADIA Pharmaceuticals, AstraZeneca, Charleston Laboratories, and others
Key Musculoskeletal Pain Therapies Rexlemestrocel-L (MPC-06-ID), Fasinumab, Resiniferatoxin, TLC599, LY3556050, LY3016859, Esreboxetine (AXS-14), Lorecivivint, CNTX-4975, Ampion, X0002, IMC-1, Buprenorphine/CAM2038, TG-C/INVOSSA/Tonogenchoncel-L, AMZ001, Joyclu, Fremanezumab, CGS-200-5, DFV890, Canakinumab, MM-II, Otenaproxesul/ATB-346, NOVOCART 3D, StroMed + platelet-rich plasma (PRP), XT-150, TNX-102 SL, ACP-044, MEDI7352, CL-108, and others
*Scope of the **Musculoskeletal Pain** Market Report*
· *Therapeutic Assessment: *Musculoskeletal Pain current marketed and emerging therapies
· *Musculoskeletal Pain* *Market Dynamics:* Attribute Analysis of Emerging Musculoskeletal Pain Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Musculoskeletal Pain Market Access and Reimbursement*
Discover more about musculoskeletal pain drugs in development @ *Musculoskeletal Pain Clinical Trials*
*Table of Contents*
1. Musculoskeletal Pain Market Key Insights
2. Musculoskeletal Pain Market Report Introduction
3. Musculoskeletal Pain Market Overview at a Glance
4. Musculoskeletal Pain Market Executive Summary
5. Disease Background and Overview
6. Musculoskeletal Pain Treatment and Management
7. Musculoskeletal Pain Epidemiology and Patient Population
8. Patient Journey
9. Musculoskeletal Pain Marketed Drugs
10. Musculoskeletal Pain Emerging Drugs
11. Seven Major Musculoskeletal Pain Market Analysis
12. Musculoskeletal Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Related Reports*
*Musculoskeletal Pain Epidemiology Forecast*
*Musculoskeletal Pain Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted musculoskeletal pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*Musculoskeletal Pain Pipeline*
*Musculoskeletal Pain Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key musculoskeletal pain companies, including *Takeda, Marinus Pharmaceuticals, SK biopharmaceuticals, CuroNZ, TAHO Pharmaceuticals, Axium Pharmaceuticals, *among others.
*Sjogren's Syndrome Pipeline*
*Sjogren's Syndrome Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Sjogren's syndrome companies, including *Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, *among others.
*Rheumatoid Arthritis Market*
*Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including *Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec, Genosco, Mesoblast, Pfizer Akros Pharma, Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone**, *among others.
*Rheumatoid Arthritis Pipeline*
*Rheumatoid Arthritis Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rheumatoid arthritis companies, including *Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, *among others.
*Other Trending Reports*
*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Frontotemporal Dementia Pipeline** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market *
*Related Healthcare Services*
*Healthcare Consulting*
*Healthcare Competitive Intelligence Services*
*Healthcare Asset Prioritization Services*
*About DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*
*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com